References
- Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68. doi:https://doi.org/10.1001/jamaoncol.2018.2706
- Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. doi:https://doi.org/10.1002/ijc.31937
- Wong MC, Lao XQ, Ho K-F, Goggins WB, Shelly L, Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):1–9.
- Quintanal-Villalonga Á, Molina-Pinelo S. Epigenetics of lung cancer: a translational perspective. Cell Oncol. 2019;42:1–18.
- Karami J, Aslani S, Jamshidi A, Garshasbi M, Mahmoudi M. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene. 2019;702:8–16. doi:https://doi.org/10.1016/j.gene.2019.03.033
- Soltanzadeh-Yamchi M, Shahbazi M, Aslani S, Mohammadnia-Afrouzi M. MicroRNA signature of regulatory T cells in health and autoimmunity. Biomed Pharmacother. 2018;100:316–23. doi:https://doi.org/10.1016/j.biopha.2018.02.030
- Aslani S, Sobhani S, Gharibdoost F, Jamshidi A, Mahmoudi M. Epigenetics and pathogenesis of systemic sclerosis; the ins and outs. Hum Immunol. 2018;79(3):178–87. doi:https://doi.org/10.1016/j.humimm.2018.01.003
- Ahmadi M, Gharibi T, Dolati S, Rostamzadeh D, Aslani S, Baradaran B, Younesi V, Yousefi M. Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases. Biomed Pharmacother. 2017;87:596–608. doi:https://doi.org/10.1016/j.biopha.2016.12.072
- Fathollahi A, Aslani S, Jamshidi A, Mahmoudi M. Epigenetics in osteoarthritis: Novel spotlight. J Cell Physiol. 2019;234(8):12309–24. doi:https://doi.org/10.1002/jcp.28020
- Doll R, Hill B. A: Smoking and carcinoma of the lung: preliminary report. Bull World Health Organ. 1999; 77 (1):84–93. 1999
- Bach PB. Smoking as a factor in causing lung cancer. JAMA. 2009;301(5):539–41. doi:https://doi.org/10.1001/jama.2009.57
- Akhtar N, Bansal JG. Risk factors of lung cancer in nonsmoker. Curr Probl Cancer. 2017;41(5):328–39. doi:https://doi.org/10.1016/j.currproblcancer.2017.07.002
- Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Natl Compr Cancer Network. 2019;17:xlv–liii.
- Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633–7. doi:https://doi.org/10.1038/nature06885
- Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736–41. doi:https://doi.org/10.1038/ng.3002
- Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J. 2010;9:65 doi:https://doi.org/10.1186/1475-2891-9-65
- DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1689S–96S. doi:https://doi.org/10.1093/ajcn/80.6.1689S
- Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimannno M, Flandina C, Tumminello FM, Leto G. Vitamin D in cancer chemoprevention. Pharm Biol. 2015;53(10):1399–434. doi:https://doi.org/10.3109/13880209.2014.988274
- Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342–57. doi:https://doi.org/10.1038/nrc3691
- Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2303–9. doi:https://doi.org/10.1158/1055-9965.EPI-05-0335
- Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients . J Clin Oncol. 2007;25(5):479–85. doi:https://doi.org/10.1200/JCO.2006.07.5358
- Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu W-D, Engler KL, Page RL, Trump DL. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother Pharmacol. 2008;62(5):881–91.
- Zhu K, Bruce D, Austin N, Devine A, Ebeling PR, Prince RL. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone‐related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res. 2008;23(8):1343–8.
- Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther. 2004;3(3):373–81.
- Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89(5):552–72. doi:https://doi.org/10.1079/BJN2003837
- Ge N, Chu X‑M, Xuan Y‑P, Ren D‑Q, Wang Y, Ma K, Gao H‑J, Jiao W‑J. Associations between abnormal vitamin D metabolism pathway function and non-small cell lung cancer. Oncol Lett. 2017;14:7538–44. doi: https://doi.org/10.3892/ol.2017.7162
- Aguirre M, Manzano N, Salas Y, Angel M, Díaz-Couselo FA, Zylberman M. Vitamin D deficiency in patients admitted to the general ward with breast, lung, and colorectal cancer in Buenos Aires, Argentina. Arch Osteoporos. 2016;11(1):4. doi: https://doi.org/10.1007/s11657-015-0256-x
- Shaffer PL, Gewirth DT. Structural basis of VDR-DNA interactions on direct repeat response elements. Embo J. 2002;21(9):2242–52. doi:https://doi.org/10.1093/emboj/21.9.2242
- Skrajnowska D, Bobrowska-Korczak B. Potential molecular mechanisms of the anti-cancer activity of vitamin D. Anticancer Res. 2019;39(7):3353–63. doi:https://doi.org/10.21873/anticanres.13478
- Uitterlinden AG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56. doi:https://doi.org/10.1016/j.gene.2004.05.014
- Bouillon R, Verlinden L, Eelen G, De Clercq P, Vandewalle M, Mathieu C, Verstuyf A. Mechanisms for the selective action of Vitamin D analogs. J Steroid Biochem Mol Biol. 2005;97(1-2):21–30. doi:https://doi.org/10.1016/j.jsbmb.2005.06.013
- Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, et al. Vitamin D deficiency 2.0: An update on the current status worldwide. Eur J Clin Nutr. 2020;74:1–16.
- Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662–87. doi:https://doi.org/10.1210/er.2004-0002
- Maj E, Filip-Psurska B, Świtalska M, Kutner A, Wietrzyk J. Vitamin D analogs potentiate the antitumor effect of imatinib mesylate in a human A549 lung tumor model. Int J Mol Sci. 2015;16(11):27191–207. doi:https://doi.org/10.3390/ijms161126016
- Chapuy M-C, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporosis Int. 1997;7(5):439–43.
- Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1, 25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 1996;56(2):264–7.
- Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700. doi:https://doi.org/10.1038/nrc2196
- McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem. 2001;276(28):26365–73. doi:https://doi.org/10.1074/jbc.M010101200
- McGaffin KR, Chrysogelos SA. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells . J Mol Endocrinol. 2005;35(1):117–33. doi:https://doi.org/10.1677/jme.1.01813
- Verone-Boyle AR, Shoemaker S, Attwood K, Morrison CD, Makowski AJ, Battaglia S, Hershberger PA. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. Oncotarget. 2016;7(1):995–1013. doi:https://doi.org/10.18632/oncotarget.6493
- Shen Z, Zhang X, Tang J, Kasiappan R, Jinwal U, Li P, Hann S, Nicosia SV, Wu J, Zhang X, et al. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol Cell Endocrinol. 2011;338(1-2):58–67. doi:https://doi.org/10.1016/j.mce.2011.02.023
- Carlberg C, Muñoz A. An update on vitamin D signaling and cancer. Semin Cancer Biol. 2020; doi:https://doi.org/10.1016/j.semcancer.2020.05.018
- Okudela K, Woo T, Kitamura H. KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol Int. 2010;60(10):651–60. doi:https://doi.org/10.1111/j.1440-1827.2010.02580.x
- Wang X, Studzinski GP. Kinase suppressor of RAS (KSR) amplifies the differentiation signal provided by low concentrations 1,25-dihydroxyvitamin D3. J Cell Physiol. 2004;198(3):333–42. doi:https://doi.org/10.1002/jcp.10443
- de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–33. doi:https://doi.org/10.21037/tlcr.2018.05.06
- Wang J, Zhao Y, Kauss MA, Spindel S, Lian H. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur J Cell Biol. 2009;88(2):103–15. doi:https://doi.org/10.1016/j.ejcb.2008.05.003
- Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD. Cramer SD: 1, 25‐dihydroxyvitamin D3 and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate. 2010;70(15):1658–71.
- Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2765–72. doi:https://doi.org/10.1158/1055-9965.EPI-09-0490
- Gao Y, Ge G, Ji H. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell. 2011;2(2):99–107. doi:https://doi.org/10.1007/s13238-011-1021-6
- Jin H-O, Seo S-K, Woo S-H, Kim Y-S, Hong S-E, Yi J-Y, Noh W-C, Kim E-K, Lee J-K, Hong S-I, et al. Redd1 inhibits the invasiveness of non-small cell lung cancer cells. Biochem Biophys Res Commun. 2011;407(3):507–11. : doi:https://doi.org/10.1016/j.bbrc.2011.03.047
- Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, Hewison M. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. Faseb J. 2011;25(3):937–47. doi:https://doi.org/10.1096/fj.10-172577
- Mavroeidi A, O’Neill F, Lee PA, Darling AL, Fraser WD, Berry JL, Lee WT, Reid DM, Lanham-New SA, Macdonald HM, et al. Seasonal 25-hydroxyvitamin D changes in British postmenopausal women at 57 N and 51 N: A longitudinal study. J Steroid Biochem Mol Biol. 2010;121(1–2):459–61. :
- Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland ØS, Moan J. Seasonal and geographical variations in lung cancer prognosis in Norway: does vitamin D from the sun play a role? Lung Cancer. 2007;55(3):263–70.
- Hirani V, Tull K, Ali A, Mindell J. Urgent action needed to improve vitamin D status among older people in England! Age Ageing. 2010;39(1):62–8.
- Mohr S, Garland C, Gorham E, Grant W, Garland F. Could ultraviolet B irradiance and vitamin D be associated with lower incidence rates of lung cancer? J Epidemiol Community Health. 2008;62(1):69–74.
- Liu J, Dong Y, Lu C, Wang Y, Peng L, Jiang M, Tang Y, Zhao Q. Meta-analysis of the correlation between vitamin D and lung cancer risk and outcomes. Oncotarget. 2017;8(46):81040–51.
- Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res. 2009;29(9):3699–704.
- Kilkkinen A, Knekt P, Heliovaara M, Rissanen H, Marniemi J, Hakulinen T, Aromaa A. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Prev Biomarkers. 2008;17(11):3274–8.
- Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, Albanes D. Serum 25-hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control study. PLoS One. 2011;6(6):e20796.
- Freedman DM, Looker AC, Chang S-C, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. 2007;99(21):1594–602. doi:https://doi.org/10.1093/jnci/djm204
- Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988–2006). Cancer Res. 2010;70(21):8587–97.
- Muller DC, Hodge AM, Fanidi A, Albanes D, Mai XM, Shu XO, Weinstein SJ, Larose TL, Zhang X, Han J, et al. No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3). Ann Oncol. 2018;29(6):1468–75.:doi:https://doi.org/10.1093/annonc/mdy104
- Wei H, Jing H, Wei Q, Wei G, Heng Z. Associations of the risk of lung cancer with serum 25-hydroxyvitamin D level and dietary vitamin D intake: A dose-response PRISMA meta-analysis. Medicine (Baltimore)). 2018;97(37):e12282 doi:https://doi.org/10.1097/md.0000000000012282
- Higashimoto Y, Ohata M, Nishio K, Iwamoto Y, Fujimoto H, Uetani K, Suruda T, Nakamura Y, Funasako M, Saijo N, et al. 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 1996;16(5A):2653–9.
- Güzey M, Sattler C, DeLuca H. Combinational Effects of Vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 1998;249(3):735–44. doi:https://doi.org/10.1006/bbrc.1998.9186
- Saito T, Okamoto R, Haritunians T, O’Kelly J, Uskokovic M, Maehr H, Marczak S, Jankowski P, Badr R, Koeffler HP, et al. Novel Gemini vitamin D3 analogs have potent antitumor activity. J Steroid Biochem Mol Biol. 2008;112(1–3):151–6.
- Samuel S, Sitrin MD. Vitamin D's role in cell proliferation and differentiation. Nutr Rev. 2008;66(10 Suppl 2):S116–S124. doi:https://doi.org/10.1111/j.1753-4887.2008.00094.x
- Maj E, Filip-Psurska B, Milczarek M, Psurski M, Kutner A, Wietrzyk J. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Int J Oncol. 2018;52(2):337–66. doi:https://doi.org/10.3892/ijo.2017.4228
- Muhammad R, Aslam A, Umber J, Khan M-u-R, Azeem W, Aftab H, Anjum A, Abid M, Khan AH, Ayoub HH, et al. Immunomodulatory role of vitamin D in infectious and non-infectious diseases. HV. 2019;6(5):115–29.
- Vanoirbeek E, Krishnan A, Eelen G, Verlinden L, Bouillon R, Feldman D, Verstuyf A. The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Best Pract Res Clin Endocrinol Metab. 2011;25(4):593–604. ) doi:https://doi.org/10.1016/j.beem.2011.05.001
- Sharma K, Goehe RW, Di X, Hicks MA, Torti SV, Torti FM, Harada H, Gewirtz DA. A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy. 2014;10(12):2346–61. doi:https://doi.org/10.4161/15548627.2014.993283
- Upadhyay SK, Verone A, Shoemaker S, Qin M, Liu S, Campbell M, Hershberger PA. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) signaling capacity and the epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC): implications for use of 1,25(OH)2D3 in NSCLC treatment. Cancers (Basel)). 2013;5(4):1504–21. doi:https://doi.org/10.3390/cancers5041504
- Škovierová H, Okajčeková T, Strnádel J, Vidomanová E, Halašová E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J Mol Med. 2018;41(3):1187–200. doi:https://doi.org/10.3892/ijmm.2017.3320
- Maeda Y, Yamato H, Hirai T, Kobori N, Fujii T, Kobayashi Y, Saitoh K, Inoguchi E, Hakozaki M, Iijima H, et al. Antitumor and other effects of 24R,25-dihydroxycholecalciferol in Lewis lung carcinoma causing abnormal calcium metabolism in tumor-bearing mice . Oncology. 1988;45(3):202–5. doi:https://doi.org/10.1159/000226562
- Rita M, Young I, Halpin J, Wang J, Wright MA, et al.: 1α. 25-dihydroxyvitamin D3 plus γ-interferon blocks lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immunosuppressor cells. Cancer Res. 1993;53:6006–10.
- Young MR, Ihm J, Lozano Y, Wright MA, Prechel MM. Prechel MM: Treating tumor-bearing mice with vitamin D 3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother. 1995;41(1):37–45.
- Young MR, Lozano Y, Ihm J, Wright MA, Prechel MM. Prechel MM: Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett. 1996;104(2):153–61.
- Prechel MM, Lozano Y, Wright MA, Ihm J, Young MRI. Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D3 treatments to block induction of immunosuppressive granulocyte/macrophage progenitor cells . Cancer Immunol Immunother. 1996;42(4):213–20. doi:https://doi.org/10.1007/s002620050273
- Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. 2005;26(6):1044–54. doi:https://doi.org/10.1093/carcin/bgi049
- Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer . Carcinogenesis. 2005;26(2):429–40. doi:https://doi.org/10.1093/carcin/bgh332
- Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. Metastatic growth of lung cancer cells is extremely reduced in Vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2004;89-90:545–7.
- Zhuravel E, Efanova O, Shestakova T, Glushko N, Mezhuev O. Administration of vitamin D3 improves antimetastatic efficacy of cancer vaccine therapy of Lewis lung carcinoma. Exp Oncol. 2010;32(1):33–9.
- Wietrzyk J, Nevozhay D, Filip B, Milczarek M, Kutner A. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 2007;27(5A):3387–98.
- Mernitz H, Smith DE, Wood RJ, Russell RM, Wang XD. Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in the A/J mouse model: evidence of retinoid mitigation of vitamin D toxicity. Int J Cancer. 2007;120(7):1402–9. doi:https://doi.org/10.1002/ijc.22462
- Koohdani F, Baghdadchi J, Sasani F, Mohammad K, Mehdipour P. Effects of vitamin D in lung, stomach, esophagus and testis tissues following administration of urethane in balb/c mice. Saudi Med J. 2008;29:340.
- Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma . J Lab Clin Med. 1999;133(2):120–8. doi:https://doi.org/10.1016/s0022-2143(99)90004-5
- Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS. Vitamin D repletion reduces the progression of premalignant squamous lesions in the NTCU lung squamous cell carcinoma mouse model. Cancer Prev Res (Phila). 2015;8(10):895–904. doi: https://doi.org/10.1158/1940-6207.Capr-14-0403
- Mondul AM, Weinstein SJ, Moy KA, Ma Nnisto S, Albanes D. Circulating 25-hydroxyvitamin D and prostate cancer survival. Cancer Epidemiol Biomarkers Prev. 2016;25(4):665–9. doi: https://doi.org/10.1158/1055-9965.Epi-15-0991
- Deschasaux M, Souberbielle J-C, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, et al. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. Br J Nutr. 2016;115(2):305–14. :doi:https://doi.org/10.1017/s0007114515004353
- Trummer O, Langsenlehner U, Krenn-Pilko S, Pieber TR, Obermayer-Pietsch B, Gerger A, Renner W, Langsenlehner T. Vitamin D and prostate cancer prognosis: a Mendelian randomization study. World J Urol. 2016;34(4):607–11. doi:https://doi.org/10.1007/s00345-015-1646-9
- Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab. 2011;25(4):605–15. doi:https://doi.org/10.1016/j.beem.2011.06.006
- Alavi Foumani A, Mehrdad M, Jafarinezhad A, Nokani K, Jafari A. Impact of vitamin D on spirometry findings and quality of life in patients with chronic obstructive pulmonary disease: a randomized, double-blinded, placebo-controlled clinical trial. COPD. 2019;14:1495–501. doi: https://doi.org/10.2147/copd.S207400
- Musarurwa C, Zijenah LS, Mhandire DZ, Bandason T, Mhandire K, Chipiti MM, Munjoma MW, Mujaji WB. Higher serum 25-hydroxyvitamin D concentrations are associated with active pulmonary tuberculosis in hospitalised HIV infected patients in a low income tropical setting: a cross sectional study. BMC Pulm Med. 2018;18(1):67. doi: https://doi.org/10.1186/s12890-018-0640-6
- Tangpricha V, Lukemire J, Chen Y, Binongo JNG, Judd SE, Michalski ES, Lee MJ, Walker S, Ziegler TR, Tirouvanziam R, et al. Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial. Am J Clin Nutr. 2019;109(3):544–53. doi:https://doi.org/10.1093/ajcn/nqy291
- Dastan F, Salamzadeh J, Pourrashid MH, Edalatifard M, Eslaminejad A. Effects of high-dose Vitamin D replacement on the serum levels of systemic inflammatory biomarkers in patients with acute exacerbation of chronic obstructive pulmonary disease. COPD: J Chron Obs Pulm Dis. 2019;16(3–4):278–83.
- Koeffler HP, Hirji K, Itri L. Itri L: 1, 25-dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep. 1985;69(12):1399–407.
- Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel . Clin Pharmacol Ther. 2002;72(6):648–59. doi:https://doi.org/10.1067/mcp.2002.129305
- Tao M-H, Dai Q, Chen S, Freudenheim JL, Rohan T, Wakelee H, Datta M, Wactawski-Wende J. Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative. Lung Cancer. 2017;110:42–7. doi:https://doi.org/10.1016/j.lungcan.2017.06.002
- Akiba T, Morikawa T, Odaka M, Nakada T, Kamiya N, Yamashita M, Yabe M, Inagaki T, Asano H, Mori S, et al. Vitamin D supplementation and survival of patients with non-small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Clin Cancer Res. 2018;24(17):4089–97. : doi: https://doi.org/10.1158/1078-0432.Ccr-18-0483
- Gold DR, Litonjua AA, Carey VJ, Manson JE, Buring JE, Lee I-M, Gordon D, Walter J, Friedenberg G, Hankinson JL, et al. Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemp Clin Trials. 2016;47:185–95. :doi:https://doi.org/10.1016/j.cct.2016.01.003
- Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol. 2011;123(1–2):30–6. doi:https://doi.org/10.1016/j.jsbmb.2010.10.002
- Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME, et al. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Prev Biomarkers. 2008;17(5):1104–10.
- Gheliji T, Oskooei VK, Ashrafi Hafez A, Taheri M, Ghafouri-Fard S. Evaluation of expression of vitamin D receptor related lncRNAs in lung cancer. Noncoding RNA Res. 2020;5(3):83–7. doi:https://doi.org/10.1016/j.ncrna.2020.05.001
- Imani D, Razi B, Khosrojerdi A, Lorian K, Motallebnezhad M, Rezaei R, Aslani S. Vitamin D receptor gene polymorphisms and susceptibility to urolithiasis: a meta-regression and meta-analysis. BMC Nephrol. 2020;21(1):1–18.
- Makoui M, Aslani S, Mohammadi P, Razi B. Vitamin D receptor gene polymorphisms and the risk of the type 1 diabetes: a meta-analysis based on 40 case–control studies. 2020.
- Haznadar M, Krausz KW, Margono E, Diehl CM, Bowman ED, Manna SK, Robles AI, Ryan BM, Gonzalez FJ, Harris CC, et al. Inverse association of vitamin D(3) levels with lung cancer mediated by genetic variation. Cancer Med. 2018;7(6):2764–75.: doi: https://doi.org/10.1002/cam4.1444
- Kong J, Chen X, Wang J, Li J, Xu F, Gao S, Yu H, Qian B. Genetic polymorphisms in the vitamin D pathway and non-small cell lung cancer survival. Pathol Oncol Res. 2020;26(3):1709–15. doi:https://doi.org/10.1007/s12253-019-00702-4
- Li M, Liu X, Liu N, Yang T, Shi P, He R, Chen M. Association between polymorphisms of vitamin d receptor and lung cancer susceptibility: evidence from an updated meta-analysis. J Cancer. 2019;10(16):3639–49. doi:https://doi.org/10.7150/jca.33431
- Maj E, Trynda J, Maj B, Gębura K, Bogunia-Kubik K, Chodyński M, Kutner A, Wietrzyk J. Differential response of lung cancer cell lines to vitamin D derivatives depending on EGFR, KRAS, p53 mutation status and VDR polymorphism. J Steroid Biochem Mol Biol. 2019;193:105431. doi:https://doi.org/10.1016/j.jsbmb.2019.105431
- Berridge MJ. Vitamin D cell signalling in health and disease. Biochem Biophys Res Commun. 2015;460(1):53–71. doi:https://doi.org/10.1016/j.bbrc.2015.01.008